<DOC>
	<DOCNO>NCT00567255</DOCNO>
	<brief_summary>The purpose study determine whether combination naltrexone SR bupropion SR safe effective treatment obesity .</brief_summary>
	<brief_title>A Safety Efficacy Study Naltrexone SR/Bupropion SR Overweight Obese Subjects</brief_title>
	<detailed_description>Two Phase II clinical trial demonstrate combination bupropion SR naltrexone associate great weight loss naltrexone alone , bupropion SR alone placebo subject uncomplicated obesity . The current study investigate safety efficacy combination naltrexone SR bupropion SR compare placebo obese subject uncomplicated obesity overweight/obesity hypertension and/or dyslipidemia .</detailed_description>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Female male subject age 18 65 year ( inclusive ) Body mass index ( weight [ kg ] /height [ m² ] ) ≥30 ≤45 kg/m² subject uncomplicated obesity , BMI ≥27 ≤45 kg/m² subject obesity control hypertension and/or dyslipidemia Normotensive ( systolic ≤140 mm Hg diastolic ≤90 mm Hg ) . Antihypertensive medication allow exception alphaadrenergic blocker clonidine . Medical regimen stable least 6 week prior randomization . Medications treatment dyslipidemia allow long medical regimen stable least 6 week prior randomization . Free opioid medication 7 day prior randomization No clinically significant abnormality serum albumin , blood urea nitrogen ( BUN ) , creatinine , bilirubin , sodium , potassium , chloride , calcium phosphorus Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) within 2.5 time upper limit normal ( ULN ) No clinically significant abnormality hematocrit , white blood cell ( WBC ) count , WBC differential , platelet Fasting glucose &lt; 126 mg/dL receive hypoglycemic agent fast triglyceride level &lt; 400 mg/dL No clinically significant abnormality urinalysis Thyroid stimulate hormone ( TSH ) within normal limit normal triiodothyronine ( T3 ) , TSH normal limit Female subject childbearing potential negative serum pregnancy test Negative urine drug screen ( UDS ) An IDSSR score &lt; 2 individual item : 5 ( sadness ) , 6 ( irritability ) , 7 ( anxiety/tension ) , 18 ( suicidality ) IDSSR total score &lt; 30 Female subject childbearing potential nonlactating agree continue use effective contraception throughout study 30 day discontinuation study drug Able comply require study procedure schedule Able speak read English Provided write informed consent Obesity know endocrine origin ( e.g. , untreated hypothyroidism , Cushing 's syndrome ) Serious medical condition ( include limit renal hepatic insufficiency ; Class III IV congestive heart failure , history angina pectoris , myocardial infarction , claudication , acute limb ischemia within previous 6 month ; lifetime history stroke ) History malignancy within previous 5 year , exception nonmelanoma skin cancer surgically cure cervical cancer Lifetime history serious psychiatric illness , include lifetime history bipolar disorder , schizophrenia psychosis , bulimia , anorexia nervosa Current serious psychiatric illness include severe personality disorder ( e.g. , borderline antisocial ) , current severe major depressive disorder , recent ( previous 6 month ) suicide attempt , current active suicidal ideation recent hospitalization due psychiatric illness Response bipolar disorder question indicate presence bipolar disorder Required medication treatment psychiatric disorder ( exception shortterm insomnia ) within previous 6 month prior randomization History drug alcohol abuse dependence ( exception nicotine dependence ) within 1 year prior study initiation Type I Type II diabetes mellitus Screening ECG correct QT ( QTc ) interval ( use Bazett 's formula &gt; 450 millisecond ( msec ) [ male ] &gt; 470 msec [ female ] ) presence clinically significant cardiac abnormality , include limited pattern consistent myocardial ischemia , electrolyte abnormality , atrial ventricular dysrhythmia significant conduction abnormality Received exclude concomitant medication : psychotropic agent ( include antipsychotic , antidepressant , anxiolytic , mood stabilizer anticonvulsant agent agent treatment attention deficit disorder ) exception lowdose benzodiazepine hypnotic agent treatment insomnia ( 2 mg lorazepam/day equivalent dose benzodiazepine hypnotic agent ) ; anorectic weight loss agent ; thecounter dietary supplement herbs psychoactive , appetite weight effect ; alphaadrenergic blocker ; dopamine agonist ; clonidine ; coumadin ; theophylline ; cimetidine ; oral corticosteroid ; cholestyramine ; cholestypol ; DepoProvera® ; smoke cessation agent ; use opioid opioidlike analgesic , include analgesic antitussive History surgical device ( e.g. , gastric banding ) intervention obesity History seizures etiology , predisposition seizure ( e.g. , history cerebrovascular accident , head trauma ≥5 minute loss consciousness , concussion symptom last ≥15 minute , brain surgery , skull fracture , subdural hematoma , febrile seizure ) History treatment bupropion naltrexone within precede 12 month History hypersensitivity intolerance bupropion naltrexone Initiation discontinuation tobacco product include inhaled tobacco ( e.g. , cigarette , cigar , pipe , etc ) , chew tobacco snuff within 3 month prior randomization plan study participation . Use nicotine replacement product ( e.g. , nicotine gum , patch , etc ) study participation allow Used drug , herb , dietary supplement believe significantly affect body weight participated weight loss management program within one month prior randomization Loss gain &gt; 4.0 kilogram within previous 3 month prior randomization Females pregnant breastfeeding planning become pregnant study period within 30 day discontinue study drug Planned surgical procedure could impact conduct study Received investigational drug use experimental device procedure within previous 30 day Participated previous clinical trial conduct Orexigen Had condition opinion investigator make subject unsuitable inclusion study Investigators , study personnel , sponsor representative immediate family</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Obesity</keyword>
</DOC>